21 – 30 of 605
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Comprehensive biobanking strategy with clinical impact at the European Cancer Moonshot Lund Center
(
- Contribution to journal › Scientific review
-
Mark
Assessing the feasibility of HPV screening for cervical cancer in pregnant women in Ethiopia
(
- Contribution to journal › Article
-
Mark
Implementation of standard of care CAR-T-cell treatment for patients with aggressive B-cell lymphoma and acute lymphoblastic leukemia in Sweden : LYMPHOMA
(
- Contribution to journal › Letter
-
Mark
Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor : The AGITG ALT-GIST intergroup randomized phase II trial: Clinical Studies
(
- Contribution to journal › Article
-
Mark
Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy : Results from the prospective GHSG–NLG phase II BVB trial
(
- Contribution to journal › Letter
-
Mark
Serious illness conversations and quality of end-of-life care in patients with hematological malignancies-a retrospective quality improvement study
(
- Contribution to journal › Article
-
Mark
Response-Letter to the Editor : Consensus Statements on End-Of-Life Care in ICU
(
- Contribution to journal › Article
-
Mark
Melanoma Proteomics Unveiled : Harmonizing Diverse Data Sets for Biomarker Discovery and Clinical Insights via MEL-PLOT
(
- Contribution to journal › Article
-
Mark
Temporal trends in relative survival of diffuse large B-cell lymphoma in Sweden and Denmark in the era of targeted and cellular therapies
(
- Contribution to journal › Letter
-
Mark
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH) : a randomised, open-label, phase 2/3 superiority trial
2025) In The Lancet(
- Contribution to journal › Article